Human TAFA1/FAM19A1 Antibody

Catalog #: AF5154 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF5154
AF5154-SP

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TAFA1/FAM19A1 Antibody Summary

Species Reactivity

Human

Specificity

Detects human TAFA1/FAM19A1 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant human (rh) TAFA3 and rhTAFA4 is observed, less than 10% cross-reactivity with rhTAFA2 is observed and less than 1% cross-reactivity with rhTAFA5 is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

E. coli-derived recombinant human TAFA1/FAM19A1
Ser26-Thr133
Accession # NP_998774

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Human TAFA1/FAM19A1 (Catalog # 5154-TA)

Immunohistochemistry

5-15 µg/mL

See below

Neutralization

Measured by its ability to neutralize the the enhancemment of neurite outgrowth of cortical neurons from E16-E18 rat embryos induced by TAFA-1. The Neutralization Dose (ND50) is typically 15 µg/mL in the presence of 10 µg/mL Recombinant Human TAFA-1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunohistochemistry

View Larger

TAFA1/FAM19A1 in Human Brain. TAFA1/FAM19A1 was detected in immersion fixed paraffin-embedded sections of human brain (cortex) using Goat Anti-Human TAFA1/FAM19A1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5154) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling when primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Sterile PBS to a final concentration of 0.2 mg/mL.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TAFA1/FAM19A1

TAFA1 (also FAM19A1) is a secreted, 13 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 133 amino acid (aa) precursor that contains a 19 aa signal sequence and a 114 aa mature chain. Like other members of the FAM19/TAFA family, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, in which C represents a conserved cysteine residue and X represents a noncysteine amino acid (1). Human TAFA1 is 100% aa identical to mouse TAFA1. TAFA1 is expressed exclusively in the brain, with highest expression in the frontal cortex, temporal cortex, occipital cortex, parietal cortex and medulla, and low levels in the basal ganglion, thalamus, and cerebellum (1). The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1, 2). And third, TAFAs may control axonal sprouting following brain injury (1).

References